• Explore /
  • Poster
  • / Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC).

Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC).

Abstract Poster

Authors

null

Masatoshi Kudo

Kindai University Faculty of Medicine, Osaka, Japan

Masatoshi Kudo , Richard S. Finn , Julien Edeline , Stéphane Cattan , Sadahisa Ogasawara , Daniel H. Palmer , Chris Verslype , Vittorina Zagonel , Laetitia Fartoux , Arndt Vogel , Debashis Sarker , Gontran Verset , Stephen Lam Chan , Jennifer J. Knox , Bruno Daniele , Ellen B Gurary , Abby B. Siegel , Lokesh Jain , Ann-Lii Cheng , Andrew X. Zhu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer

Track

Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02702414

Citation

J Clin Oncol 38, 2020 (suppl 4; abstr 518)

Abstract #

518

Poster Bd #

B21

Abstract Disclosures

Similar Posters

First Author: Tim Meyer

First Author: Ann-Lii Cheng

First Author: Kazufumi Kobayashi

First Author: Arndt Vogel